Marcos Langtry

Director of Commercial Development, Allogeneic Cell Therapy • Lonza Ltd

Marcos Langtry is Head of Allogeneic Cell Therapy at Lonza. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos held several senior level positions with TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he has acquired extensive experience with aseptically filled, biologic and cell therapy products.

Also speaking

Ian Rees

Inspectorate Strategy and Innovation • MHRA

David Allison

Chief Executive • TREAT-NMD

Alexander Natz

Secretary General • EUCOPE

Event Info


2022 Spotlight Roundtables

Take a look at the 2022 sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.